NASDAQ
9.58USD
+0.15 (+1.59%)
We have scored 14 news catalysts on Senseonics Holdings, Inc. (SENS) over the past 12 months. The biggest single-day move next to one of them came May 9, 2026, when SENS closed −6.2%: “Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights”. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in price momentum and revenue growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
400.4M
P/E
—
EPS
—
Beta
0.97
52W range
4.79-11.58
Day range
9.23–9.66
Open
9.43
Prev close
9.43
Volume
1.7M
Avg volume
701.8K
Dividend
0.00
IPO
2015-12-22
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Senseonics Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SENS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
